Form 4: Mineralys Therapeutics Director Akkaraju Srinivas Acquires Stock Options

Director Akkaraju Srinivas and Samsara BioCapital, L.P. report acquisition of stock options in Mineralys Therapeutics.

Summary

• On February 13, 2025, Srinivas Akkaraju, a director and 10% owner of Mineralys Therapeutics, acquired 32,900 stock options.
• The options have an exercise price of $10.20.
• The options vest in 12 substantially equal monthly installments following the grant date.
• Samsara BioCapital, L.P. is also listed as a reporting person and 10% owner.
• Following the transaction, Akkaraju directly owns 32,900 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director and significant shareholder could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. This filing indicates changes in beneficial ownership.

Stakeholder Impact

• The acquisition of stock options by a director and significant shareholder could potentially increase investor confidence.

Key Dates

Keywords

Mineralys Therapeutics, Akkaraju Srinivas, Samsara BioCapital, stock options, Form 4, beneficial ownership, director, 10% owner